Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teicoplanin Powder in Lumbar Instrumentation Surgery
NCT04341831Phase 3
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Sponsor
- Bezmialem Vakif University
- Modality
- Small Molecules
- Drugs
- teicoplanin
- Conditions
- surgical site infection (SSI)
01
Overview
Phase 3, randomised, double-blind trial of teicoplanin in surgical site infection (SSI), sponsored by Bezmialem Vakif University. Primary endpoint: Surgical site infection at 90 days. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with lumbar spinal stenosis, disc herniation, degenerative scoliosis, or spondylolisthesis scheduled for lumbar posterior instrumentation, excluding those with malignancy, systemic inflammatory disease, severe cardiac insufficiency, morbid obesity, or prior lumbar surgery.
04
Endpoints
Primary
Surgical site infection
Beyond the preview
Go deeper on NCT04341831.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341831.